Introduction
It is well known that the mutations of EGFR act as one of the most frequent driver genes in non-small cell lung cancer (NSCLC) patients, especially among East Asian female lung adenocarcinoma patients. 1, 2 Previous studies have shown that EGFRtyrosine kinase inhibitors (EGFR-TKIs) could achieve a high response rate and yield a promising efficacy for EGFR mutants. [3] [4] [5] [6] Despite a response rate of 60%-70% in EGFR-mutated lung cancer patients treated with EGFR-TKIs, 10%-20% of individuals developed primary resistance. [4] [5] [6] The mechanism is currently ill defined. Possible contributing factors included T790M mutation, MET amplification and PIK3CA mutation. [7] [8] [9] Concomitant genetic alterations were found to be associated with primary resistance in EGFR-mutated NSCLC patients. 10, 11 However, the studies were somewhat limited, and only several case series were reported. Furthermore, the efficacies of EGFR-TKIs have remained elusive.
Here, ALK and ROS1 fusion gene panel was used for screening the patients harboring EGFR-mutated samples and further detecting the therapeutic efficacies of EGFR-TKIs. 
Materials and methods

Patient samples
Consecutive EGFR-mutated patients receiving EGFR-TKIs for lung adenocarcinoma were screened at Hangzhou Cancer Hospital between 2009 and 2015. The inclusion criteria were as follows: 1) uses of EGFR-TKIs during advanced stage; 2) sufficient residual tissues for detecting ALK and ROS1 fusion genes and 3) confirmed as having sensitive EGFR mutation. Resistant mutations such as T790M, S768I and exon 20 insertions were excluded. The study protocol was approved by the ethics committee of Hangzhou Cancer Hospital, and written informed consents were obtained from all patients.
Detection of EGFR/ALK/ROS1 fusion gene
EGFR gene was detected by amplification refractory mutation system (ARMS)-based kit (Amoy, Xiamen, China). It was capable of detecting the following 23 mutations: three in exon 18 (G719A, G719C and G719S), 13 deletions in exon 19, two mutations in exon 20 (T790M and S768I), three insertions in exon 20 and two mutations in exon 21 (L858R and L861Q).
The ALK and ROS1 fusion mRNAs were detected by polymerase chain reaction (PCR) using fusion gene detection kit (Amoy). Briefly, total RNA was extracted using Qiagen (Dusseldorf, Germany) RNeasy FFPE kit. mRNA was reverse transcribed into cDNA for 1 h at 42°C. β-actin was used as an internal control. The conditions of reverse transcription-polymerase chain reaction (RT-PCR) were as follows: initial denaturation at 95°C for 5 min, followed by 95°C for 25 s, 64°C for 20 s and 72°C for 20 s for ensuring specificity and 31 cycles at 93°C for 25 s, 60°C for 35 s and 72°C for 20 s. Data collection and sensitivity analysis were detailed previously. 12 The subtypes of EGFR/ALK/ROS1 genes are summarized in Table S1 .
evaluations of TKi treatment
Tumors were evaluated during the treatment with EGFRTKIs or ALK/ROS1 inhibitor every 8 weeks. Objective tumor responses were evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Objective response rate (ORR) included complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD).
statistical analyses
The Kaplan-Meier method was used for survival analysis. Progression-free survival (PFS) of TKIs was defined as the time from initiating TKI treatment to documented progression or mortality from any cause. Statistical analysis was performed using the SPSS 18 software (SPSS Inc., Chicago, IL, USA). The median follow-up period was 28.5 months (4.5-65 months). The last follow-up time was October 31, 2016.
Results
Patient characteristics
A total of 421 patients were enrolled, and their clinical characteristics are summarized in Table 1 . Among the patients, 13 were confirmed as having concomitant ALK/ROS1 fusion gene. Their clinical characteristics are summarized in Table 2 . There were six males and seven females with a median age of 55 years. One patient was a former smoker and 12 had never smoked. The comparisons of single EGFR versus concomitant gene mutations are listed in Table 1 .
Gene profiles
The genetic details of 421 EGFR mutations are as follows: exon 19 deletions (n=217), L858R mutation in exon 21 (n=169), G719X in exon 18 (n=21) and L861Q (n=14). Concomitant gene fusions were identified in 13 patients (3.1%), including ALK (n=10, 2.4%) and ROS1 (n=3, 0.7%). Their profiles are detailed in Table 2 . The clinical efficacies of 408 single EGFR-mutated patients included CR (n=2, 0.5%), PR (n=249, 61.0%), SD (n=87, 21.3%) and PD (n=70, 17.2%). In concomitant ALK/ROS1 mutants, the outcomes of EGFR-TKIs were PR (n=6), SD (n=3) and PD (n=4). The efficacy comparisons between single EGFR and concomitant gene mutations are shown in Table 3 .
The overall value of PFS was 10.7 months (95% CI, 10.0-11.4). The median values of PFS were 10.7 and 6.6 months in mutants of single EGFR and concomitant ALK/ROS1 fusion gene, respectively (Figure 1, P=0.004 Figure 2 ).
Discussion
Our results showed that 3.1% of EGFR-mutated lung adenocarcinoma Chinese patients harbored ALK/ROS1 fusion genes. Concurrent ALK/ROS1 gene decreased the therapeutic efficacy of EGFR-TKIs. However, it had no impact on the overall survival (OS).
Although gene alterations were presumably mutually exclusive in lung adenocarcinoma, 13 some reports 
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Mao and Wu revealed that genes might occur concomitantly. 14, 15 With the emerging of high-throughput sequencing, many concomitant genes have been detected. The frequency of concomitant EGFR/ALK or EGFR/ROS1 mutations was 3.1% in the present study, and this figure was consistent with previous reports. [16] [17] [18] [19] Owing to a low frequency of concomitant genes in EGFRmutated lung cancer patients, the efficacy of EGFR-TKIs is largely unknown. The median PFS of first-generation EGFR-TKIs was 11.2 months in patients harboring concomitant EGFR/ALK genes in one report by Yang et al. 20 For concomitant ALK/ROS1 and EGFR mutants, there was a practical dilemma of therapeutic sequence of EGFR-TKIs and ALK/ROS1 inhibitors. Relative levels of phospho-EGFR or ALK could predict the efficacy of targeted treatment in EGFR/ALK mutants in the study of Yang et al. 20 In the present study, all patients took EGFR-TKIs initially and eight took subsequent ALK/ROS1 inhibitor. The median value of PFS was 6.6 months for 13 patients on EGFR-TKIs. However, among eight patients on crizotinib, six obtained disease control. Owing to efficacy difference for dosing order of targeted therapy, despite a low frequency, there is a future need of using a useful marker for selecting targeted treatment in patients with concomitant genes. Except at the level of phosphorylation, abundance of gene was identified previously as a predictor of targeted therapy; 21 the abundance level of different genes in one sample should be detected for patients with concomitant genes.
A small sample size was a major drawback of the present study. Second, not all patients received crizotinib after ineffective EGFR-TKIs. As a result, the clinical efficacy of further treatment could not be fully evaluated. Third, only RT-PCR was used for ALK/ROS1 genes so that false positives might ensue. Moreover, RT-PCR could not provide convincing evidence for the dominance of expression for one oncogene aberration over another in the same samples. In addition, it was impossible to check whether individual tumor cells had these two mutations simultaneously or singly. 22 However, our findings are meaningful for clinical practice.
Conclusion
A total of 3.1% of EGFR-mutated patients harbored ALK/ ROS1 fusion genes. Concomitant genes of ALK/ROS1 might decrease the therapeutic efficacy of EGFR-TKIs.
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